ER-000444793

• CAT Number: I020501
• CAS Number: 792957-74-5
• Molecular Formula: C₂₃H₁₈N₂O₂
• Molecular Weight: 354.40
• Purity: ≥95%
• Target: Mitochondrial Metabolism
• IUPAC Name: N-(2-benzylphenyl)-2-oxo-1H-quinoline-4-carboxamide
• InChI: InChI=1S/C23H18N2O2/c26-22-15-19(18-11-5-7-13-21(18)24-22)23(27)25-20-12-6-4-10-17(20)14-16-8-2-1-3-9-16/h1-13,15H,14H2,(H,24,26)(H,25,27)
• InChIKey: OIZPRRGJIHYZAY-UHFFFAOYSA-N
• SMILES: C1=CC=C(C=C1)CC2=CC=CC=C2NC(=O)C3=CC(=O)NC4=CC=CC=C43

ER-000444793（Cat No.:I020501）is an investigational compound being developed by Erasca, Inc., designed to target specific genetic mutations in cancer cells, particularly those with KRAS mutations. It is a selective, small-molecule inhibitor aimed at blocking the activity of mutant KRAS, a key driver of various cancers, including non-small cell lung cancer (NSCLC) and colorectal cancer. By inhibiting KRAS, ER-000444793 has the potential to disrupt cancer cell signaling pathways, thereby inhibiting tumor growth. It is currently undergoing clinical trials to assess its efficacy, safety, and potential as a treatment for KRAS-driven cancers.

Reference

[1]. Briston T, et al. Identification of ER-000444793, a Cyclophilin D-independent inhibitor of mitochondrial permeability transition, using a high-throughput screen in cryopreserved mitochondria. Sci Rep. 2016 Nov 25;6:37798.